login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
Q32 BIO INC (QTTB) Stock News
USA
- NASDAQ:QTTB -
US7469641051
-
Common Stock
3.33
USD
+0.16 (+5.05%)
Last: 10/20/2025, 8:12:00 PM
3.3
USD
-0.03 (-0.9%)
After Hours:
10/20/2025, 8:12:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
QTTB Latest News, Press Relases and Analysis
All
Press Releases
8 days ago - By: Chartmill
- Mentions:
NVX
TMQ
ADTX
GWH
...
Unusual volume stocks in Monday's session
11 days ago - By: Chartmill
- Mentions:
GIG
TMQ
CENN
SCWO
...
Unusual volume stocks are being observed in Friday's session.
13 days ago - By: Chartmill
- Mentions:
MSN
XTLB
PCSA
SPRB
...
Traders are paying attention to the gapping stocks in Wednesday's session.
2 months ago - By: Q32 Bio
Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference
2 months ago - By: Benzinga
- Mentions:
BFLY
EPIX
CSCI
MOLN
...
12 Health Care Stocks Moving In Monday's After-Market Session
3 months ago - By: The Motley Fool
Q32 Bio (QTTB) Q2 Loss Drops 45%
4 months ago - By: Q32 Bio
Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer
6 months ago - By: Q32 Bio
Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
6 months ago - By: Stocktwits
Q32 Bio Stock Turns Retail Trader Heads After FDA Grants Fast Track For Alopecia Drug
6 months ago - By: Q32 Bio
Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata
6 months ago - By: Q32 Bio
Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
7 months ago - By: Q32 Bio
Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update
8 months ago - By: Q32 Bio
Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting
8 months ago - By: Q32 Bio
Q32 Bio to Participate in Upcoming March Investor Conferences
8 months ago - By: Benzinga
- Mentions:
CMCO
DVAX
PLYA
FLNC
This Columbus McKinnon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
8 months ago - By: Q32 Bio
Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata
9 months ago - By: Q32 Bio
Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference
10 months ago - By: Investor's Business Daily
Q32 Bio Crashes 67% On A 'Messy' Update In Eczema, Alopecia Treatment
Please enable JavaScript to continue using this application.